Yak interferon-alpha loaded solid lipid nanoparticles for controlled release

被引:21
作者
Li, Shaoyong [1 ]
Zhao, Baokai [1 ]
Wang, Fenghua [1 ]
Wang, Ming [1 ]
Xie, Shuyu [1 ]
Wang, Siliang [1 ]
Han, Chao [1 ]
Zhu, Luyan [1 ]
Zhou, Wenzhong [1 ]
机构
[1] China Agr Univ, Coll Vet Med, Dept Vet Prevent Med, Beijing 100193, Peoples R China
关键词
Yak IFN-alpha; Solid lipid nanoparticles; Antiviral activity; Toxicity; Controlled release; DELIVERY VEHICLES; FUSION PROTEIN; CYCLOSPORINE-A; DRUG-DELIVERY; SERUM-ALBUMIN; I INTERFERONS; HEPATITIS-B; SLN; MICROPARTICLES; IMMUNIZATION;
D O I
10.1016/j.rvsc.2009.06.010
中图分类号
S85 [动物医学(兽医学)];
学科分类号
0906 ;
摘要
To explore the potential of a novel animal interferon formulation for controlled release, the yak interferon-alpha (IFN-alpha) glutathione S-transferase (GST) fusion protein was expressed in Escherichia coli (E. coli) and the purified recombinant IFN-alpha was encapsulated into solid lipid nanoparticles (SLN) by double emulsion solvent evaporation (w/o/w) method. The particle size and zeta potential of IFN-alpha-loaded SLN were 124.2 +/- 10.2 nm and -11.2 +/- 0.6 mV. The encapsulation efficiency of IFN-alpha and loading capacity of the SLN were 83.7 +/- 4.5% and 1.73 +/- 0.15%, respectively. In vitro release study and antiviral assay demonstrated that the IFN-alpha released from the SLN in a 16-day period exhibited antiviral activity in Madin-Darby bovine kidney (MDBK) cells against vesicular stomatitis virus (VSV), and showed a release pattern of an initial burst release followed by a sustained and slow release. Cytotoxicity assay in cell culture demonstrated that the SLN were not toxic. The results of this exploratory study suggest that the IFN-alpha-loaded SLN could be a useful formulation for controlled release in veterinary therapeutics. (C) 2009 Elsevier Ltd. All rights reserved.
引用
收藏
页码:148 / 153
页数:6
相关论文
共 39 条
[1]   Peptide-loaded solid lipid nanoparticles (SLN): Influence of production parameters [J].
Almeida, AJ ;
Runge, S ;
Muller, RH .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1997, 149 (02) :255-265
[2]   Solid lipid nanoparticles as a drug delivery system for peptides and proteins [J].
Almeida, Antonio J. ;
Souto, Eliana .
ADVANCED DRUG DELIVERY REVIEWS, 2007, 59 (06) :478-490
[3]  
Armstrong J A, 1981, Methods Enzymol, V78, P381
[4]   USE OF RECOMBINANT BOVINE-ALPHA1 INTERFERON IN REDUCING RESPIRATORY-DISEASE INDUCED BY BOVINE HERPESVIRUS TYPE-1 [J].
BABIUK, LA ;
LAWMAN, MJP ;
GIFFORD, GA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1987, 31 (05) :752-757
[5]   The use of deferoxamine infusions to enhance the response rate to interferon-alpha treatment of chronic viral hepatitis B [J].
Bayraktar, Y ;
Koseoglu, T ;
Sommer, C ;
Kayhan, B ;
Temizer, A ;
Uzunalimoglu, B ;
DeMaria, N ;
VanThiel, DH .
JOURNAL OF VIRAL HEPATITIS, 1996, 3 (03) :129-135
[6]   INFLUENCE OF POLYBUTYLCYANOACRYLATE NANOPARTICLES AND LIPOSOMES ON THE EFFICACY AND TOXICITY OF THE ANTICANCER DRUG MITOXANTRONE IN MURINE TUMOR-MODELS [J].
BECK, P ;
KREUTER, J ;
RESZKA, R ;
FICHTNER, I .
JOURNAL OF MICROENCAPSULATION, 1993, 10 (01) :101-114
[7]   Cyclosporin nanoparticulate lipospheres for oral administration [J].
Bekerman, T ;
Golenser, J ;
Domb, A .
JOURNAL OF PHARMACEUTICAL SCIENCES, 2004, 93 (05) :1264-1270
[8]  
Bordens R, 1997, Semin Oncol, V24, pS9
[9]  
BORDENS R, 1997, SEMINARS ONCOLOGY, V24, pS49
[10]   Protection against Bordetella pertussis infection following parenteral or oral immunization with antigens entrapped in biodegradable particles:: effect of formulation and route of immunization on induction of Th1 and Th2 cells [J].
Conway, MA ;
Madrigal-Estebas, L ;
McClean, S ;
Brayden, DJ ;
Mills, KHG .
VACCINE, 2001, 19 (15-16) :1940-1950